Kereiakes, D J <br/><br/>
Abciximab provides cost-effective survival advantage in high-volume interventional practice.  [electronic resource] 

 -  American heart journal  Oct 2000 
 - 603-10 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1097-6744 
<br/><br/><label>Standard No.: </label>10.1067/mhj.2000.109647  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Angioplasty, Balloon, Coronary--mortality<br/>Antibodies, Monoclonal--economics<br/>Coronary Disease--economics<br/>Cost-Benefit Analysis<br/>Female<br/>Humans<br/>Immunoglobulin Fab Fragments--economics<br/>Male<br/>Middle Aged<br/>Ohio--epidemiology<br/>Platelet Aggregation Inhibitors--economics<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Prognosis<br/>Survival Rate--trends